Peptide Pharmacokinetics, Bioavailability & Half-Life

Pharmacokinetic half-life describes the decline of drug concentration in the body under defined in-vivo conditions. It is not refrigerator shelf life, chemical degradation rate in a vial, lyophilized storage life, or a reconstituted-product discard period -- those are vial-stability questions, answered by entirely different evidence and covered in the Peptide Stability & Degradation Evidence guide.

PLASMA HALF-LIFE IS NOT VIAL SHELF LIFE. A peptide with a long plasma half-life can still degrade in solution over time, and a peptide with a short plasma half-life is not automatically chemically unstable in the vial. These are two separate questions asked with two separate kinds of evidence.

A useful way to organize everything this guide covers is the ADME framework: Administration, Absorption, Distribution, Metabolism, and Elimination. Each stage asks a different question about what is happening to the peptide, and each stage can be influenced by different variables -- but none of them, alone, tells you the whole pharmacokinetic story.

This is a conceptual map, not a personalized prediction. It shows what each stage means and what it can be influenced by -- it does not calculate a dose, a schedule, or an individual exposure.

Drug moves from an administration site, through an absorption gate, into systemic circulation, then through distribution, and finally through metabolic, renal, and other clearance pathways. ABSORPTION DETERMINES HOW DRUG GETS IN. CLEARANCE HELPS DETERMINE HOW FAST SYSTEMIC EXPOSURE FALLS.

Absorption can be influenced by route, formulation, permeability, and local degradation. Clearance can be influenced by proteolysis, renal filtration, protein binding, and drug-specific metabolic/elimination pathways. These are two separate gates in the same journey, not one combined number.

Every administration route changes which absorption question is being asked. Intravenous delivery bypasses an absorption phase and is commonly used as the reference for absolute bioavailability -- but the absence of an absorption barrier does not make IV universally preferable. Subcutaneous, oral, intranasal/mucosal, transdermal/device-assisted, and topical routes each face their own barriers, formulation dependencies, and variables.

ROUTES CANNOT BE RANKED WITHOUT A SPECIFIC DRUG PRODUCT, TARGET, FORMULATION, AND CLINICAL PURPOSE. No route below is labeled preferred or best, and this page does not recommend an administration route.

Oral peptide delivery faces two core barriers: enzymatic/chemical degradation in the gastrointestinal environment, and poor epithelial permeability of relatively large, polar molecules. Oral peptide bioavailability is generally low unless a particular molecule/formulation successfully addresses those barriers.

This is not a universal rule with no exceptions -- successful oral peptide products can depend heavily on formulation-specific delivery technology, as the oral semaglutide/SNAC case study below shows. Being an oral product does not by itself mean a molecule naturally crosses the gut wall well.

Peptides frequently have limited passive membrane permeability, and distribution often favors plasma and extracellular spaces rather than unrestricted intracellular partitioning. Protein binding and target binding can modify distribution in drug-specific ways -- not every peptide has the same volume of distribution.

VOLUME OF DISTRIBUTION IS AN APPARENT PK PARAMETER, NOT A LITERAL BODY-FLUID VOLUME MEASUREMENT. It is a proportionality term relating amount in the body to measured concentration, not an anatomic container.

Small, unbound peptides may pass through glomerular filtration and then undergo renal handling/metabolism -- kidney elimination can involve filtration followed by metabolism rather than intact urinary recovery. Only the unbound fraction is freely filterable in the simple model, and protein binding can reduce that free fraction and reduce filtration.

This is CONCEPTUAL -- DRUG-SPECIFIC PK CAN DIFFER. Published molecular-weight thresholds are approximate and depend on shape, charge, binding, and physiology, so this page does not publish a hard universal cutoff.

Molecular protraction changes the molecule's systemic PK behavior itself -- protease resistance, albumin binding, and larger conjugates/fusions are examples. Formulation-based protraction instead changes the rate of release or input from the administration site -- depot systems and controlled-release formulations are examples. A slow-release formulation can make absorption the rate-limiting process without necessarily changing the peptide's intrinsic systemic clearance.

MOLECULAR HALF-LIFE EXTENSION AND FORMULATION-BASED PROTRACTION ARE NOT THE SAME THING. Depot release and molecular half-life extension are not equivalent, even when both prolong how long drug action is observed.

This is a formulation-specific approved-product example, drawn from current FDA labeling plus the mechanistic Science Translational Medicine study on SNAC-enabled gastric absorption. It does not include food/water/fasting administration instructions, and the specific PK numbers below do not transfer to research or compounded formulations.

ORAL ABSORPTION TECHNOLOGY SOLVES AN ENTRY PROBLEM; SEMAGLUTIDE'S MOLECULAR DESIGN SOLVES MUCH OF THE SYSTEMIC HALF-LIFE PROBLEM. Low oral bioavailability and a long systemic elimination half-life can coexist in the same approved product -- they are answers to two different pharmacokinetic questions.

Comparing the three approved-product examples side by side shows why bioavailability and half-life must be tracked separately: injectable semaglutide's high SC bioavailability and oral semaglutide's low gastric bioavailability both resolve to the same approximately one-week elimination half-life once the drug is systemically absorbed, while tirzepatide combines a different absolute bioavailability with a shorter multi-day half-life.

APPROVED-PRODUCT PK EXAMPLES ONLY -- NOT TRANSFERABLE TO OTHER PEPTIDES, COMPOUNDED PRODUCTS, OR RESEARCH VIALS. BIOAVAILABILITY AND HALF-LIFE ARE DIFFERENT AXES OF PHARMACOKINETICS.

A few widely repeated claims about peptide pharmacokinetics, bioavailability, and half-life do not hold up against the guidance and literature they are often attributed to.